Nov 16, 2026 · 3 min readIncretin AnalogsClinical Trials
CagriSema REDEFINE 9: Phase 3b Results at Two Lower Doses
Phase 3b REDEFINE 9 (Lancet Diabetes & Endocrinology): about 21% mean weight change at 68 weeks vs 2.0% with placebo in 309 adults.

On 14 November 2026, The Lancet Diabetes & Endocrinology published REDEFINE 9, a phase 3b trial of cagrilintide-semaglutide (CagriSema) at two lower dose levels than those used in earlier phase 3 studies. In the 68-week study, adults with overweight or obesity who received the combination had a mean body-weight change of about -21%, compared with -2.0% for pooled placebo (Wharton et al., Lancet Diabetes Endocrinol 2026). The study was funded by Novo Nordisk.
What the trial was
REDEFINE 9 (NCT06388187) was a multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3b trial run at 24 sites in Canada, France, Germany, the United Kingdom and the United States. Participants were adults aged 18 or older with a BMI of at least 30 kg/m², or at least 27 kg/m² plus one or more obesity-related complication, and without diabetes.
Of 333 people assessed, 309 were randomly assigned between June and October 2024. The full analysis set was 104 participants in the higher of the two combination dose levels, 103 in the lower dose level, and 102 in a pooled placebo group. Treatment was given subcutaneously once a week for 68 weeks, with nutrition and physical activity counselling until week 74. Mean age was 48.0 years, mean BMI 39.1 kg/m², and 77% of participants were women.
The main results
The two co-primary endpoints were the relative change in body weight from baseline to week 68 and the proportion of participants with a weight reduction of at least 5%. Using the efficacy estimand:
- Mean weight change: -20.7% (SE 0.9) at the higher dose level, -21.0% (SE 1.0) at the lower dose level, and -2.0% (SE 1.0) with pooled placebo.
- Difference vs placebo: -18.8 percentage points (95% CI -21.5 to -16.0) at the higher dose level and -19.0 percentage points (95% CI -21.8 to -16.2) at the lower dose level; p<0.0001 for both.
- At least 5% weight reduction: 95.1% at the higher dose level and 96.3% at the lower dose level, versus 33.4% with placebo (differences of 61.7 and 63.0 percentage points, p<0.0001 for both).
The two combination groups therefore had very similar mean outcomes. The authors concluded that both dose levels were superior to placebo and suggested that different dose levels might support treatment flexibility.
Safety and completion
Of 309 participants, 291 (94%) completed the study and 254 (82%) were still on treatment at week 68. Adverse events were reported in 99% of the higher-dose group, 95% of the lower-dose group and 91% of the placebo group. The authors report that most were mild or moderate and gastrointestinal in nature. No deaths were reported.
Context
According to the paper, CagriSema at the higher doses used in earlier global phase 3 studies has already produced clinically meaningful weight reductions. REDEFINE 9 asked a different question: whether lower dose levels, reached with a shorter escalation period, could achieve similar results. Because the trial has no head-to-head comparison between its own dose levels and the earlier studies' doses, cross-trial comparisons should be made with caution. The population was also limited to adults without diabetes, and the sponsor funded the trial.
Cagrilintide is an amylin analogue and semaglutide a GLP-1 receptor agonist; the combination is investigational in this setting. The ClinicalTrials.gov record lists the study as completed, with a final completion date of 22 April 2026.
What comes next
The paper does not report outcomes beyond 68 weeks. Regulatory timing for CagriSema is a matter for the sponsor and the relevant agencies and is not addressed in the publication.
Sources
Sources
For research use only. Not for human or animal consumption. This article summarizes published research for scientific information only. It is not medical advice and makes no claim about any use in people or animals. These products have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). They are not intended to diagnose, treat or prevent any disease.